The Association of the British Pharmaceutical Industry (ABPI) has suspended Novo Nordisk’s membership for two years and will be auditing the company over that time following its finding that the company breached the association’s code of practice.

The suspension is related to a complaint to the Prescription Medicines Code of Practice Authority (PMCPA) — the self-regulatory body that administers the ABPI code — that Novo Nordisk offered a weight management services course in which the only product mentioned was Novo Nordisk’s and that the company did not make clear its involvement in the training.

Under the terms of the suspension, Novo Nordisk will undergo audits by the PMCPA in 2023 and 2024 to check for “clear, significant, and then sustained improvement” in its compliance with the industry standards.